Evidence map›Paper›PMID 40775338›Full record

ArticleJournal of translational medicine2025

SREBF1-mediated SND1 transcriptional activation promotes prostate cancer progression via MTDH interaction through the SESN2/AMPK/mTOR axis.

Yijie Tang, Yufan Ying, Xueyou Ma, Jiahe Yi, Zixiang Liu, Yuqing Wu, Shen Lin, Xuan Shu, Zhixiang Qi, Jindan Luo and 4 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yijie Tang *Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China.
Yufan Ying *Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China.
Xueyou MaDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China.
Jiahe YiDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China.
Zixiang LiuDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China.
Yuqing WuDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China.
Shen LinDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China.
Xuan ShuDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China.
Zhixiang QiDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China.
Jindan LuoDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China.
Xiangyi ZhengDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China.
Jiangfeng LiDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China. lijf@zju.edu.cn.
Liping XieDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China. xielp@zju.edu.cn.
Ben LiuDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China. drliuben@zju.edu.cn.ORCID 0000-0002-0709-6784

Funding

National Natural Science Foundation of China 81972374National Natural Science Foundation of China 82072848National Natural Science Foundation of China 82103243National Natural Science Foundation of China 82273132National Natural Science Foundation of China 82473375Natural Science Foundation of Zhejiang Province LQ21H160026Natural Science Foundation of Zhejiang Province LQN25H160039Natural Science Foundation of Zhejiang Province LY21H160038Zhejiang Provincial Postdoctoral Science Foundation ZJ2024077
6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is a prevalent cancer and a major cause of cancer-related deaths in men worldwide. Growing evidence indicates that Staphylococcal nuclease and Tudor domain containing 1 (SND1) is a multifunctional protein extensively involved in transcriptional regulation, RNA maturation, post-transcriptional modifications, and other processes. However, previous studies have rarely investigated the function of SND1 as an RNA-binding protein in PCa tumorigenesis.

methodsThe Cancer Genome Atlas and NCBI Gene Expression Omnibus (GEO) databases were used to evaluate SND1 expression levels in PCa. We conducted a series of in vitro and in vivo functional experiments to assess the biological functions of SND1, including cell counting kit-8, colony formation, Transwell and wound-healing assays, and animal experiments in nude mice. Chromatin immunoprecipitation, dual-luciferase reporter assay, and DNA pull-down assay were performed to validate the association between the upstream transcription factor and SND1. Based on mass spectrometry, RNA-seq, and RNA immunoprecipitation (RIP)-seq, we identified the downstream targets of SND1- Sestrin 2 (SESN2), which were validated through qRT-PCR, Western blotting, RIP-qPCR, dual-luciferase reporter assay, and RNA pull-down assay. Finally, a series of functional assays and Western blotting analyses confirmed SESN2 as a downstream target of SND1.

resultsOur research identified that SND1 was significantly elevated in PCa, and knocking down SND1 repressed PCa multiplication and migration. Mechanistically, sterol regulatory element binding transcription factor 1 (SREBF1) bound to the promoter of the SND1 gene and activated its transcription, which subsequently formed a complex with metadherin (MTDH). This complex is directly bound to and degraded SESN2 mRNA, and disruption of this interaction with C26-A6 inhibited MTDH-SND1-mediated SESN2 degradation. Notably, SESN2 expression was inhibited in PCa and may exert tumor-suppressive effects by affecting the AMPK/mTOR signaling pathway. Rescue experiments indicated that knocking down SND1 or MTDH significantly inhibited PCa proliferation and migration, and knocking down SESN2 partially reversed this effect.

conclusionsOur study reveals SND1 overexpression in PCa, which is transcriptionally activated by SREBF1. Mechanistically, SND1 interacts with MTDH and promotes SESN2 mRNA degradation, modulating PCa progression through the AMPK/mTOR pathway.

Indexed as

AMP-Activated Protein KinasesDisease ProgressionEndonucleasesHeat-Shock ProteinsMembrane ProteinsNuclear ProteinsProstatic NeoplasmsRNA-Binding ProteinsTOR Serine-Threonine KinasesTranscriptional ActivationAnimalsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansAMP-Activated Protein KinasesEndonucleasesHeat-Shock ProteinsMembrane ProteinsNuclear ProteinsRNA-Binding ProteinsSESN2 protein, humanSestrinsSND1 protein, humanSREBF1 protein, humanSterol Regulatory Element Binding Protein 1TOR Serine-Threonine KinasesMTDHmTORProstate cancerSESN2SND1

Identifiers

PMID40775338
PMCPMC12333249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.